Cannabix Technologies to Attend U.S. National Drug and Alcohol Conference to Market Marijuana Breath Test
Cannabix Technologies (OTC: BLOZF) announces its participation in the upcoming National Drug and Alcohol Screening Association (NDASA) conference in Florida, where it will showcase its Marijuana Breath Test (MBT) alongside strategic partner Omega Laboratories.
The announcement follows Omega Laboratories' recent validation of the Cannabix MBT, which can simultaneously quantify Δ-9-THC, Δ-8-THC, CBD, and CBN in breath aerosols. The MBT system, comprising a Breath Collection Unit and Breath Cartridge, focuses on detecting recent marijuana use, unlike traditional urine, blood, and saliva tests that can detect THC for extended periods.
With cannabis now legal for medical use in 39 states and recreational use in 24 states, Cannabix is positioning itself at the forefront of breath-based drug detection. The company is currently conducting an operational review to scale up manufacturing, sales, marketing, and support capabilities in anticipation of growing demand.
Cannabix Technologies (OTC: BLOZF) annuncia la sua partecipazione alla prossima conferenza della National Drug and Alcohol Screening Association (NDASA) in Florida, dove presenterà il suo Marijuana Breath Test (MBT) insieme al partner strategico Omega Laboratories.
L'annuncio segue la recente validazione del Cannabix MBT da parte di Omega Laboratories, che può quantificare simultaneamente Δ-9-THC, Δ-8-THC, CBD e CBN negli aerosol respiratori. Il sistema MBT, composto da un'unità di raccolta del respiro e una cartuccia per il respiro, si concentra sul rilevamento dell'uso recente di marijuana, a differenza dei test tradizionali su urine, sangue e saliva che possono rilevare il THC per periodi prolungati.
Con la cannabis ora legale per uso medico in 39 stati e per uso ricreativo in 24 stati, Cannabix si sta posizionando in prima linea nella rilevazione di droghe basata sul respiro. L'azienda sta attualmente conducendo una revisione operativa per aumentare le capacità di produzione, vendita, marketing e supporto in previsione di una crescente domanda.
Cannabix Technologies (OTC: BLOZF) anuncia su participación en la próxima conferencia de la National Drug and Alcohol Screening Association (NDASA) en Florida, donde presentará su Marijuana Breath Test (MBT) junto a su socio estratégico Omega Laboratories.
El anuncio sigue a la reciente validación del Cannabix MBT por parte de Omega Laboratories, que puede cuantificar simultáneamente Δ-9-THC, Δ-8-THC, CBD y CBN en aerosoles respiratorios. El sistema MBT, que consta de una Unidad de Recolección de Aliento y una Cartucho de Aliento, se centra en detectar el uso reciente de marihuana, a diferencia de las pruebas tradicionales de orina, sangre y saliva que pueden detectar THC durante períodos prolongados.
Con la cannabis ahora legal para uso médico en 39 estados y uso recreativo en 24 estados, Cannabix se está posicionando a la vanguardia de la detección de drogas basada en el aliento. La empresa está llevando a cabo una revisión operativa para aumentar sus capacidades de fabricación, ventas, marketing y soporte en anticipación de una creciente demanda.
캐나빅스 테크놀로지스 (OTC: BLOZF)는 플로리다에서 열리는 국가 약물 및 알코올 검사 협회(NDASA) 회의에 참석하여 전략적 파트너인 오메가 연구소와 함께 대마초 호흡 테스트(MBT)를 선보일 것이라고 발표했습니다.
이번 발표는 오메가 연구소가 캐나빅스 MBT를 최근 검증한 결과로, 이 테스트는 호흡 에어로졸에서 Δ-9-THC, Δ-8-THC, CBD 및 CBN을 동시에 정량화할 수 있습니다. MBT 시스템은 호흡 수집 장치와 호흡 카트리지로 구성되어 있으며, 전통적인 소변, 혈액 및 타액 검사와 달리 최근의 대마초 사용을 감지하는 데 중점을 두고 있습니다.
현재 39개 주에서 의학적 용도로, 24개 주에서 오락적 용도로 대마초가 합법화됨에 따라, 캐나빅스는 호흡 기반 약물 탐지의 최전선에 자리 잡고 있습니다. 회사는 증가하는 수요를 예상하여 제조, 판매, 마케팅 및 지원 능력을 확장하기 위해 운영 검토를 진행 중입니다.
Cannabix Technologies (OTC: BLOZF) annonce sa participation à la prochaine conférence de la National Drug and Alcohol Screening Association (NDASA) en Floride, où elle présentera son Marijuana Breath Test (MBT) en collaboration avec son partenaire stratégique Omega Laboratories.
Cette annonce fait suite à la validation récente du Cannabix MBT par Omega Laboratories, qui peut quantifier simultanément Δ-9-THC, Δ-8-THC, CBD et CBN dans des aérosols respiratoires. Le système MBT, composé d'une unité de collecte de souffle et d'une cartouche de souffle, se concentre sur la détection de l'utilisation récente de marijuana, contrairement aux tests traditionnels d'urine, de sang et de salive qui peuvent détecter le THC pendant de longues périodes.
Avec la cannabis désormais légale à des fins médicales dans 39 États et à des fins récréatives dans 24 États, Cannabix se positionne à la pointe de la détection des drogues basée sur le souffle. L'entreprise effectue actuellement un examen opérationnel pour augmenter ses capacités de fabrication, de vente, de marketing et de soutien en prévision d'une demande croissante.
Cannabix Technologies (OTC: BLOZF) kündigt seine Teilnahme an der bevorstehenden Konferenz der National Drug and Alcohol Screening Association (NDASA) in Florida an, wo es seinen Marijuana Breath Test (MBT) zusammen mit dem strategischen Partner Omega Laboratories präsentieren wird.
Die Ankündigung folgt auf die kürzliche Validierung des Cannabix MBT durch Omega Laboratories, das Δ-9-THC, Δ-8-THC, CBD und CBN in Atemaerosolen gleichzeitig quantifizieren kann. Das MBT-System, das aus einer Atemsammlungseinheit und einer Atemkartusche besteht, konzentriert sich auf die Erkennung des kürzlichen Marihuanakonsums, im Gegensatz zu herkömmlichen Urin-, Blut- und Speicheltests, die THC über längere Zeiträume nachweisen können.
Da Cannabis jetzt in 39 Bundesstaaten für medizinische Zwecke und in 24 Bundesstaaten für Freizeitnutzung legal ist, positioniert sich Cannabix an der Spitze der atembasierten Drogenüberwachung. Das Unternehmen führt derzeit eine betriebliche Überprüfung durch, um die Produktions-, Verkaufs-, Marketing- und Unterstützungsfähigkeiten im Hinblick auf die steigende Nachfrage auszubauen.
- None.
- None.
VANCOUVER, British Columbia, April 01, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) developer of marijuana and alcohol breath testing devices is pleased to report that it will be attending the National Drug and Alcohol Screening Association (NDASA) conference in Florida in early April alongside strategic partner, Omega Laboratories, to begin joint marketing of the Company’s Marijuana Breath Test (MBT). NDASA is one of the world’s largest organizations providing education and resources for workplace safety. The conference will be attended by corporations and professionals in the drug and alcohol testing industry from around the world. This comes on the heels of a laboratory validation milestone with the Cannabix Marijuana Breath Test by strategic partner Omega Laboratories (“Omega”).
Highlights:
- Omega Laboratories of Ohio, USA, recently announced the development and validation of the Cannabix Marijuana Breath Test;
- The validation included test method for the simultaneous quantification of Δ-9-tetrahydrocannabinol (THC), Δ-8-THC, cannabidiol (CBD), and cannabinol (CBN) in breath aerosols using the Cannabix Breath Collection Unit (BCU) and Breath Cartridge (BC) (combined, referred to as the “MBT”, see Figure 1);
- Cannabix and Omega will attend NDASA in early April. This is a premier event in the U.S. for the drug and alcohol testing industry.
- Cannabix’s MBT is a collect and send solution, focused on “recent use” detection of delta-9 THC as opposed to urine, blood and saliva methods (that can detect delta-9 THC many hours, days, or even weeks after consumption) (1)
- The Company is advancing an operational review to meet manufacturing, human resources, sales, marketing, support and order fulfilment needs that are expected to grow.
Figure 1. Cannabix Breath Collection Unit with Breath Cartridge technology.
On March 18th, Omega, a leading drug testing laboratory with facilities in the United States and Canada, announced the development and validation of the Cannabix Marijuana Breath Test. The validation included a test method for the simultaneous quantification of Δ-9-tetrahydrocannabinol (THC), Δ-8-THC, cannabidiol (CBD), and cannabinol (CBN) in breath aerosols collected using Cannabix’s BCU and BC hardware. This development establishes Omega and Cannabix as new technology offering for collecting and testing breath for recent marijuana usage. Omega Laboratories is currently in the process of incorporating Cannabix's breath testing technology into its suite of services and integrating testing protocols. The Company is advancing an operational review to meet demands that are anticipated to grow.
Rav Mlait, CEO of Cannabix stated, “In the United States, cannabis legalization has grown to 39 states for medical use and 24 states legalized for recreational use. Cannabix is at the forefront of drug detection using human breath. Omega Laboratories’ validation work is a major milestone for the Company and its history of cutting-edge breath research and development. I want to commend the work of both Omega and Cannabix staff, scientists and engineers.”
(1) Olla P, Ishraque MT, Bartol S. 2020. Evaluation of Breath and Plasma Tetrahydrocannabinol Concentration Trends Postcannabis Exposure in Medical Cannabis Patients. Cannabis and Cannabinoid Res.; 99-104.
Swortwood MJ, Newmeyer MN, Andersson M, Abulseoud OA, Scheidweiler KB, Huestis MA. 2017. Cannabinoid disposition in oral fluid after controlled smoked, vaporized, and oral cannabis administration. Drug Testing and Analysis, 9(6), 905–915.
Musshoff F & Madea B. 2006. Review of biologic matrices (urine, blood, hair) as indicators of recent or ongoing cannabis use. Ther Drug Monit. 28(2),155-63.
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a developer of marijuana and alcohol breath testing technologies for a range of workplaces, law enforcement and other settings. Breath testing for delta-9 THC (the primary psychoactive ingredient in cannabis) would allow employers and law enforcement to identify recent marijuana use. Cannabix is the developer of the Breath Logix autonomous alcohol screening device for organizations who strive to improve alcohol safety and monitoring.
We seek Safe Harbor.
On behalf of the Board of Directors
“Rav Mlait”
CEO
Cannabix Technologies Inc.
For further information, contact the Company at info@cannabixtechnologies.com
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
Cautionary Statement Regarding Forward-Looking Statements
This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates," "plan," "continue," "expect," "project," "intend," "believe," "anticipate," "estimate," "may," "will," "potential," "proposed," "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements in this news release include, but are not limited to, statements relating to: certification of devices, acceptance of devices by international regulators, the achievement of any or all of the goals and aims of the strategic partnership and development agreement with Omega Laboratories; the completion of pre-validation or validation testing described in this news release; final development of a commercial or prototype product(s); the successful trial or pilot of company technologies; the commercialization of the Company's products; the negotiation and potential entry into additional agreements with distributors; and the completion of future financings. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information. Important factors that could cause actual results to differ materially from those expressed in the forward-looking information include (but are not limited to): adverse market conditions; risks regarding protection of proprietary technology; the ability of the Company to complete future financings; the ability of the Company to develop and market its future product; risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition; that Omega may not complete all or any of the milestones as contemplated strategic partnership and development agreement with Omega Laboratories; that the CSE may not approve the issuance of the securities; that the Company’s development of breathalyzer technology will provide any benefit to the Company; there is no assurance that any proposed new products will be built, will be successful in beta testing or clinical trials; there is no assurance that the Company will enter into any partnerships to advance any of its corporate initiatives or technologies; there is no assurance that any “patent pending” or “provisional patents” technologies licensed by the Company or owned by the Company will receive patent status by regulatory authorities; the Company is not currently selling breathalyzers and there is no assurance that the Company ever will; and other factors beyond the control of the Company. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3b71cc49-8924-4c8e-a404-516ee7d8050b
FAQ
What is the key feature of Cannabix Technologies' (BLOZF) Marijuana Breath Test?
What compounds can the BLOZF Marijuana Breath Test detect?
When will Cannabix Technologies (BLOZF) present at the NDASA conference?
How many states currently allow cannabis use where BLOZF could potentially operate?
What recent milestone has BLOZF achieved with Omega Laboratories?
